百洋医药
(301015)
| 流通市值：132.02亿 | | | 总市值：132.04亿 |
| 流通股本：5.26亿 | | | 总股本：5.26亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 3,559,509,826.79 | 1,783,828,902.3 | 7,506,514,889.15 | 5,627,105,173.24 |
| 营业总成本 | 3,218,418,246.24 | 1,584,783,180.55 | 6,840,247,859.66 | 4,964,392,143.68 |
| 其他经营收益 | | | | |
| 营业利润 | 339,026,220.51 | 194,034,590.16 | 736,266,227.22 | 706,472,533.66 |
| 利润总额 | 338,141,517.03 | 193,581,079.36 | 722,975,024.62 | 695,288,726.28 |
| 净利润 | 279,948,368.1 | 155,458,342.19 | 571,929,272.87 | 560,613,786.74 |
| 每股收益 | | | | |
| 其他综合收益 | -1,201,107.64 | 586.44 | -5,215,824.27 | -1,351,003.28 |
| 综合收益总额 | 278,747,260.46 | 155,458,928.63 | 566,713,448.6 | 559,262,783.46 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 5,444,631,543.65 | 6,114,441,794.15 | 5,717,712,971.31 | 5,341,242,262.97 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,537,598,065.42 | 2,453,437,854.79 | 2,394,537,014.23 | 2,250,194,126.74 |
| 资产总计 | 7,982,229,609.07 | 8,567,879,648.94 | 8,112,249,985.54 | 7,591,436,389.71 |
| 流动负债: | | | | |
| 流动负债合计 | 3,809,150,921.26 | 4,278,362,722.74 | 3,977,428,107.96 | 3,441,378,304.6 |
| 非流动负债: | | | | |
| 非流动负债合计 | 1,442,714,031.38 | 1,390,876,704.58 | 1,392,973,506.62 | 1,386,290,913.96 |
| 负债合计 | 5,251,864,952.64 | 5,669,239,427.32 | 5,370,401,614.58 | 4,827,669,218.56 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 2,394,682,060.11 | 2,588,824,336.06 | 2,463,146,954.84 | 2,481,532,375.26 |
| 股东权益合计 | 2,730,364,656.43 | 2,898,640,221.62 | 2,741,848,370.96 | 2,763,767,171.15 |
| 负债和股东权益合计 | 7,982,229,609.07 | 8,567,879,648.94 | 8,112,249,985.54 | 7,591,436,389.71 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 4,472,107,743.94 | 2,253,961,517.99 | 8,439,678,080.91 | 6,420,978,563.77 |
| 经营活动现金流出小计 | 4,434,100,285.13 | 2,231,044,691.38 | 7,505,224,476.05 | 5,799,560,998.56 |
| 经营活动产生的现金流量净额 | 38,007,458.81 | 22,916,826.61 | 934,453,604.86 | 621,417,565.21 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 211,258,498.84 | 88,066,499.52 | 348,104,559.7 | 236,800,667.34 |
| 投资活动现金流出小计 | 546,264,061.01 | 276,003,109.05 | 936,910,315.11 | 766,370,662.08 |
| 投资活动产生的现金流量净额 | -335,005,562.17 | -187,936,609.53 | -588,805,755.41 | -529,569,994.74 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 2,257,531,960 | 1,112,016,033.82 | 2,487,816,664.51 | 2,235,685,474.72 |
| 筹资活动现金流出小计 | 2,164,204,542.54 | 606,513,344.15 | 2,122,337,858.7 | 1,892,813,853.79 |
| 筹资活动产生的现金流量净额 | 93,327,417.46 | 505,502,689.67 | 365,478,805.81 | 342,871,620.93 |
| 汇率变动对现金及现金等价物的影响 | -9,515,962.26 | -4,424,046.32 | -9,730,307.46 | -6,340,154.17 |
| 现金及现金等价物净增加额 | -213,186,648.16 | 336,058,860.43 | 701,396,347.8 | 428,379,037.23 |
| 期末现金及现金等价物余额 | 1,710,755,893.69 | 2,260,001,402.28 | 1,923,942,541.85 | 1,650,925,231.28 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -213,186,648.16 | - | 701,396,347.8 | - |
最新报告期：2026-09-17| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 东方证券 | 伍云飞,袁润璞 | 0.95 | 1.19 | 1.36 | 2026-09-17 |
| 华鑫证券 | 胡博新 | 1.01 | 1.26 | 1.58 | 2026-09-09 |
| 华源证券 | 刘闯 | 0.95 | 1.17 | 1.28 | 2026-09-09 |